ABSTRACT
Zika virus (ZIKV) has emerged as a serious health threat in the Americas and the Caribbean. ZIKV is transmitted by the bite of an infected mosquito, sexual contact, and blood transfusion. ZIKV can also be transmitted to the developing fetus in utero, in some cases resulting in spontaneous abortion, fetal brain abnormalities, and microcephaly. In adults, ZIKV infection has been correlated with Guillain-Barre syndrome. Despite the public health threat posed by ZIKV, neither a vaccine nor antiviral drugs for use in humans are currently available. We have identified an amphibian host defense peptide, Yodha, which has potent virucidal activity against ZIKV. It acts directly on the virus and destroys Zika virus particles within 5 min of exposure. The Yodha peptide was effective against the Asian, African, and South American Zika virus strains and has the potential to be developed as an antiviral therapeutic in the fight against Zika virus. The peptide was also effective against all four dengue virus serotypes. Thus, Yodha peptide could potentially be developed as a pan-therapeutic for Zika and dengue viruses.
Subject(s)
Amphibians/metabolism , Antiviral Agents/pharmacology , Dengue Virus/drug effects , Dengue/drug therapy , Peptide Fragments/pharmacology , Zika Virus Infection/drug therapy , Zika Virus/drug effects , Animals , Dengue/virology , Hemolysis/drug effects , Humans , Mice , Mice, Inbred C57BL , Zika Virus Infection/virologyABSTRACT
Here, we report two novel peptides identified from the skin secretion, having homologies to Lividin and Spinulosain, of an endemic frog, Hydrophylax bahuvistara, of Western Ghats. This is the first report of these peptides from Indian frogs and first identification of Lividin from the Hydrophylax genus. Both peptides exhibited weak antimicrobial activity but very low haemolytic activity. The problems of naming amphibian host defense peptides (HDPs) are also discussed.
